ErbB2/HER2 governs CDK4 inhibitor sensitivity and timing and irreversibility of G1/S transition by altering c-Myc and cyclin D function
Ichikawa, A. N.; Murakami, K.; Aoki, K.; Okada, M.
Show abstract
Cell cycle entry and the irreversible transition from the G1 to S phase are crucial for mammalian cell proliferation. Among the ErbB family, the ErbB2/HER2 receptor is a key driver of cancer growth. However, the quantitative mechanisms underlying the ErbB2-mediated G1/S transition remain unclarified. Here, we performed an extensive time-course analysis of high and low ErbB2-expressing breast cancer cells to describe the regulatory mechanisms of the ErbB2-mediated G1/S transition. Live-cell imaging using cell cycle reporters revealed that the G1/S transition occurs 20 h after ErbB2 activation, driven primarily by the cyclin D1/CDK4-RB axis. Hsp90 is regulated by CDK4 activity and controls the stability of ErbB2 protein in a time-dependent manner. CDK4 inhibitor treatment arrested the cell cycle in most cells; a subpopulation showed a 25-h delay in G1/S entry associated with enhanced c-Myc activation. In high ErbB2-expressing cells, CDK4 inhibition led to c-Myc overactivation, a rapid decrease in cyclin D1 expression, and cell cycle arrest. Overall, we demonstrate how ErbB2 receptor levels modulate the roles of cyclin D1 and c-Myc in the G1/S transition and suggest that variations in ErbB2 levels within breast cancer tissues confer heterogeneous sensitivity to CDK4 inhibitors, potentially complicating treatment.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- YAP1 induces invadopodia formation by transcriptionally activating TIAM1 through its enhancer in breast cancer 95%
- Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53 93%
- Loss of EIF4G2 Mediates Aggressiveness in Distinct Human Endometrial Cancer Subpopulations with Poorer Survival Outcome in Patients 93%
Similar papers in this journal
- Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma 94%
- The apparent requirement for protein synthesis during G2 phase is due to checkpoint activation 94%
- BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer 93%
Similar papers in this journal
- Development of Small Molecule Inhibitors Targeting PBX1 Transcription Signaling as a Novel Cancer Therapeutic Strategy 93%
- Activation of AKT induces EZH2-mediated beta-catenin trimethylation in colorectal cancer 93%
- A Non-genetic Mechanism for Chemoresistance in Lung Cancer: The Role of Integrin β4/Paxillin Axis 93%
Similar papers in this journal
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 94%
- Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells 94%
- Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.